PDCD1 and neoplasm: The utilization of the anti-PD-1 antibody pembrolizumab has emerged as a beacon of hope, boasting anti-tumor effectiveness and a tolerable safety profile within the realm of treating patients with recurrent or metastatic gastric cancer [35].